Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]

Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]

The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor […]

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have […]

The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present […]

Chemotherapy commonly alters cellular redox balance and increases the oxidative state. Recent studies have reported that chemoresistant cells have an […]